The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Figure 1: The approval of Andexxa was supported by data from two Phase 3 ANNEXA studies (ANNEXA-R and ANNEXA-A), which evaluated the safety and efficacy of the drug in reversing the anticoagulant activity of the factor Xa inhibitors rivaroxaban and apixaban. This chart shows the reversal response for rivaroxaban.
Figure 2: The approval of Andexxa was supported by data from two Phase 3 ANNEXA studies (ANNEXA-R and ANNEXA-A), which evaluated the safety and efficacy of the drug in reversing the anticoagulant activity of the factor Xa inhibitors rivaroxaban and apixaban. This chart shows the reversal response for apixaban.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

San Diego Cardiovascular Interventions Symposium

San Diego Alliance of Cardiovascular Professionals Cardio Conference 2018

Phoenix Alliance of Cardiovascular Professionals Cardio Conference 2018

International Dead Sea Symposium on Innovations and Controversies in Cardiac Arrhythmias

Echo on Marco Island: Case-Based Approach

The Heart Beat of Cardiology

Coronary Artery Disease: Case-Based Learning

Echo Best Practice: Echocardiography in Patient Care & Clinical Trials

Cardiovascular Review in Bahrain: A Case-Based Approach

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now